We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current UMRX market cap is 259.59M. The company's latest EPS is USD -2.3163 and P/E is -1.01.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -58.23M | -62.4M | -64.39M | -75.41M | -73.73M |
| Net Income | -54.37M | -58.35M | -58.95M | -70.63M | -67.93M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 7.87M | 0 | 0 | 0 | 0 |
| Operating Income | -82.2M | -75.55M | -147.84M | -208.13M | -275.94M |
| Net Income | -74.81M | -72.27M | -140.24M | -192.41M | -255.86M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 313.44M | 476.11M | 429.94M | 384.02M | 327.9M |
| Total Liabilities | 55.64M | 53.78M | 56.71M | 69.36M | 71.61M |
| Total Equity | 257.8M | 422.33M | 373.22M | 314.66M | 256.29M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 250.92M | 232.09M | 300.81M | 313.44M | 327.9M |
| Total Liabilities | 16.25M | 17.91M | 45.08M | 55.64M | 71.61M |
| Total Equity | 234.67M | 214.18M | 255.74M | 257.8M | 256.29M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -153.62M | -52.53M | -95.23M | -147.21M | -207.79M |
| Investing | -97.82M | 1.04M | -83.58M | -23.4M | 38.28M |
| Financing | 163.54M | 214.06M | 213.8M | 214.43M | 214.45M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -35.85M | -58.76M | -118.64M | -153.62M | -207.79M |
| Investing | 8.42M | -1.72M | -124.72M | -97.82M | 38.28M |
| Financing | 232.2M | 37.98M | 163.56M | 163.54M | 214.45M |
| Market Cap | 259.59M |
| Price to Earnings Ratio | -1.01 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.64 |
| Price to Book Ratio | 1.01 |
| Dividend Yield | - |
| Shares Outstanding | 110.46M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.05 (2.08%) |
| Company Name | Unum Therapeutics Inc |
| Address |
838 walker road dover, delaware 19904 |
| Website | https://www.unumrx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
